Although itching (or pruritus) in a scar is a very common and distressing symptom and is increasingly being recognized as a significant obstacle in burn rehabilitation, the exact mechanisms underlying this symptom have not been elucidated; hence, a reliable therapy has not been established. Scar formation occurs as a part of a multistage wound healing process when body tissues are damaged by a physical injury or impact. In particular, hypertrophic scar formation may occur as a result of deep burns.
Scar formation occurs as a part of a multistage wound healing process when body tissues are damaged by a physical injury or impact. In particular, hypertrophic scar formation may occur as a result of deep burns. 1 Hypertrophic scars might be itchy and painful and cause serious functional and cosmetic disability in many burn survivors. Therefore, almost all burn patients complain about their appearance and cacesthesia, such as itch or pruritus and pain. A previous study reported that the most common and distressful complications in burn patients were abnormal appearance (75.2%), itch (73.3%), and pain (67.6%). 2 Itch in the hypertrophic scar continues to be a major obstacle in the rehabilitation of severe burn patients. It usually begins at the time of wound closure and then peaks at approximately 3 to 12 months or much later. The deeper the burn, the longer the time taken to heal; reepithelialization may increase the risk of developing significant itch. In addition, there may be a relationship between the itch and the site of injury. The itch might further lead to related psychological disturbances, such as anxiety, depression, and sleeplessness. 3 As a result, the quality of life in these patients is markedly impaired.
Although many studies have investigated itch and its influencing factors, the mechanism of itch has not yet been elucidated. The pathogenesis of pruritus in hypertrophic scars is poorly understood, and hence, there is a lack of effective treatment for itch. 4 Recently, substantial progress has been made in research into the mechanism of itch in burn patients, and the results are promising. 5, 6 This review article summarizes the evidence supporting the potential role of opioids and their receptors in pruritus in burn patients.
RELATIONSHIP BETWEEN PRURITUS AND PAIN
Pain is an unpleasant sensory and emotional experience, which is usually associated with actual or potential tissue damage. Itch was first defined 340 years ago by Samuel Hafenreffer as "an unpleasant sensation provoking the desire to scratch"; this definition is still widely used. 7 Many stimuli are known to induce pruritus. 8 The basic mechanisms of itch and the interactions between pain and itch have been long debated. Nevertheless, there is an obvious differentiation between neurons involved in the generation of itch and pain, at least in the peripheral regions. 9 Itch is clearly distinct from pain with respect to the subjective sensation, the inducing stimuli, and the reflex patterns. In contrast to pain-related withdrawal reflexes, itching evokes the characteristic scratching reflex. However, both itch and pain share many similarities and are closely related. 10, 11 In general, the itch sensation can be reduced by the painful sensations produced by scratching. The inhibition of itch by painful stimuli has been experimentally demonstrated using various painful thermal, mechanical, and chemical stimuli. 12 The layer hypothesis (elicitation of pain and itch in the periphery) is described as follows: a strong stimulus induces the dermal unmyelinated afferent C-fibers, resulting in the pain sensation; a weak stimulus induces the epidermal unmyelinated afferent C-fibers, resulting in the itch sensation.
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POSSIBLE MECHANISM(S) OF PRURITUS IN BURN PATIENTS
Pruritus is known to be extremely common in postburn patients, with a reported incidence of 57 to 100% in children and 25 to 87% in adults.
14 Although the exact mechanism of postburn itching is unclear, previous studies have shown that itch (burn and nonburn) might be caused (or induced) by histamine, neurokinin, tachykinins, bradykinin, and neuropeptides. 4 In addition to the aforementioned factors, other cytokines and growth factors (eg, nerve growth factor, neurotrophins 3 and 4, interleukin-2, interferon, and tumor necrosis factor-␣) have been reported to induce itching in nonburn patients. 10, 15 In other words, itch is one of the most common symptoms and might have many clinical classifications, and there are different peripheral itch mediators and receptors involved in various pruritic diseases. 10, 16 Nonburn-induced itch may have a unifactorial origin, but burn-induced itch may have a multifactorial origin, including factors such as the release of inflammatory mediators and injury to the peripheral nerve.
In addition, a host of other inflammatory mediators, such as kinins and substance P, are present in an inflammatory wound, and these mediators can increase histamine release and potentiate the pruritogenic effects of histamine. 19 Mast cells are multifunctional cells, and studies have suggested that these cells may be capable of regulating inflammation. Mast cells continue their maturation and differentiation in the peripheral tissues, developing into two well-described subsets of cells, namely, MC(T) (tryptaseϩ, chymaseϪ) and MC(TC) (tryptaseϩ, chymaseϩ) cells. These cells can be distinguished based on their tissue location, dependence on T lymphocytes, and their granule contents. Mast cells have a functional and anatomical association with sensory nerves in the skin. Activation of peripheral sensory nerves may lead to the release of mediators, such as neuropeptides and neurotrophins, which are capable of activating mast cells. After activation, mast cells release histamine, leukotrienes, prostanoids, proteases, many growth factors, and cytokines, which in turn can excite and stimulate the surrounding neuropeptidecontaining C-fibers. This possibly results in the initiation of a feed-forward loop and potentiation of neurogenic inflammation. 20, 21 From the neural point of view, the itch sensation is transmitted by C-fibers. At least three subtypes of Cfiber afferents are potentially involved in inducing the itch sensation. These C-fibers include the CMi(Hisϩ) (histamine receptor positive, mechanoinsensitive Cfiber afferents), which is most commonly associated with itch; C-Mi(His-), which responds to capsaicin, acetylcholine, and bradykinin; and mechano-and heat-responsive C-nociceptor (mechanosensitive Cfiber afferents), which also responds to certain pruritogenic molecules. Schmelz et al 22 reported that CMi(Hisϩ) units might be "selective" but not "specific" for pruritogenic substances and that the pruritic potency of a mediator increases with its ability to activate CMi(Hisϩ) units but decreases with the activation of mechano-and heat-responsive C-nociceptor and CMi(HisϪ) units. Moreover, the C-fiber terminals may express different receptors, such as histamine receptors, opioid receptors (ORs), substance P receptors, and neurokinin-1/2 receptors. 4 Histamine is released from the mast cells when tissues are stimulated by different factors. 23 Once it is released, histamine-induced itch is triggered by unmyelinated C-fibers. 24 Histamine receptors are known to medi-ate histamine-inducedresponsesthroughtheG-proteincoupled receptor pathway. Four subtypes of histamine receptors have been identified to date. Histamine receptor subtype I (H1R) has been studied most extensively in the context of histamineinduced itch. In fact, H1R blockers (antihistamines) are widely used to manage and alleviate itch symptoms. 25 However, the itch-reducing efficacies of these classical H1R antihistamines are debatable because some believe that the effect is attributable to sedation rather than to H1R antagonism. 26 In contrast to the proven relationship between H1R and itch induction, the involvement of histamine receptor subtype II (H2R) is less convincing. It is generally believed that H2R is, at best, only marginally involved in the histamine-induced itch process. 25 For instance, dimaprit (a H2R agonist) failed to cause scratching, and cimetidine (a H2R antagonist) failed to suppress histamine-induced itch in BalbC mice. 27 Moreover, it is intriguing that the antagonists of histamine receptor subtype III (H3R) aggravate itch symptoms, and this seems to contradict the aforementioned histamine-induced itch pathway. 28 Currently, it seems that the itch elicited by H3R antagonism is mediated by substance P, another itch-inducing agent. 29 The activation of histamine receptor subtype IV (H4R) increases intracellular Ca 2ϩ levels, possibly by coupling with the phospholipase Cdependent pathway in mast cells. 30 This may explain why histamine does not play an exclusive and essential role in generating itch; further, antihistamines were effective in only approximately 20% of the patients. 4, 31 The itch in burn patients may be caused by inflammation and C-fiber damage. The itch develops in the skin, which is or has recently been inflamed, and is often associated with postburn hypertrophic scars. These sites can be in the areas of skin where healing has been delayed and reinnervation of the peripheral nerves has been affected. The tissue injury present in a burn induces a significant increase in plasma histamine 32 and local release of bradykinin, substance P, neurokinin A, and other tachykinins. 33, 34 These released substances can bind the C-fiber receptors and upregulate the C-fiber activation process. In an area of deep dermal burn, a loss of the substance P-positive fibers was recorded immediately after the injury. Two weeks after the burn injury, the density of substance P-positive fibers was higher in the injured skin than in the normal skin. Similar findings have also been reported in other inflammatory disorders such psoriasis, atopic dermatitis, and bullous pemphigoid. 35 Therefore, it is likely that the itch experienced by burn survivors is caused by many pruritogenic mediators through the C-fiber receptors. The itch sensation is maintained by a constant replenishment of mediators released by the mast and inflammatory cells into a region of increased density of sensitized nerve fibers. 4, 36 Another noteworthy role of opioids is that they possess analgesic properties. Recently, LaSalle et al 37 reported that 72% of the patients using naltrexone were satisfied with the itch relief, 69% were able to decrease the dose of or discontinue other medications to reduce itch, 85% would recommend it to other burn patients, and 62% disclosed that it improved their quality of life. The success of naltrexone, an opioid antagonist, in treating pruritus in nonburn patients suggested that it may also be effective in burn survivors.
Observational evidence suggests that pruritus and pain associated with hypertrophic scars are involved in the reinnervation pattern of healing wounds and scars. Henderson et al 38 reported that in an experimental model of excisional skin wound, the density of protein gene product 9.5, a pan-neuronal marker, peaked between 14 and 42 days posttreatment, and the levels of protein gene product 9.5 decreased to approximately those levels found in unwounded skin by 84 days (mature scar). We observed an increase in the number of nerve fiber-like structures in human hypertrophic scars; this finding was consistent with the aforementioned findings and suggested a significant correlation between the reinnervation pattern of healing wounds and scars as well as the pain and pruritus occurring in hypertrophic scars. In addition, our recent studies have shown that ␤-endorphin and -OR (MOR) were distributed in nerve terminals at the border of the dermis and epidermis during the wound healing process in rats with deep partial-thickness scalds. 39 OR antagonists reduced experimentally evoked histamine-induced itch of the skin. However, the interaction between opioid peptides and histamine and between opioid peptides and nerves in the generation of itch must be further explored.
PAIN, ITCH, AND OPIOID RECEPTORS
For several decades, opioids and their receptors have been identified as integral components in the generation of pain. 40 In particular, the peripheral analgesic effects of opioids have been shown in adults, and local application of opioids has been used for treating several painful conditions including a variety of skin diseases. 41, 42 Itch can be reduced by painful stimuli, but analgesia may reduce this inhibition and thus enhance itch. 43 Further, itch is suppressed by capsaicininduced secondary mechanical hyperalgesia. 44 Generally, the itch sensation can be reduced by the painful sensations caused by scratching. The inhibition of itch by painful stimuli has been experimentally demonstrated by using various pain inducers, such as thermal, cold, mechanical, and chemical stimuli. 12, 45 These noxious stimuli primarily evoked pain in control subjects and patients with psoriasis vulgaris. However, patients with atopic dermatitis experienced itching instead of a burning pain. This might explain why itch is the predominant sensation in the lesional skin. 46 In peripheral tissues, opioid agonists, such as morphine or methadone (but not fentanyl or oxymorphone), cause local itching. In contrast, after intrathecal or epidural administration of opioids, patients typically scratch the nose, perinasal area, and upper part of the face. 47 This phenomenon could be explained by the high concentration of ORs in the spinal nucleus of the trigeminal nerve innervating the face. This phenomenon is particularly relevant to spinally administered MOR agonists, which induce segmental analgesia often combined with segmental pruritus. 48 Given that MOR can induce itch, it is not surprising that MOR antagonists have antipruritic effects in animal models of itch 49 and also in patients with cholestatic itch. In some of the cholestatic patients, the reduction of itch by naloxone was unexpectedly accompanied by the induction of pain 50 and withdrawal-like reactions 51 ; this suggested an upregulation of endogenous opioids in these patients. Conversely, -OR (KOR) antagonists enhanced itch in animal experiments. Kamei and Nagase 52 found that when norbinaltorphimine was subcutaneously injected into the rostral back, the mice would scratch the skin around the injection site with their hind paws. In line with these results, the KOR agonist nalbuphine has been shown to reduce MOR-induced pruritus in a meta-analysis. 53 This new therapeutic concept has already been tested successfully in patients with chronic pruritus secondary to uremia by using a newly developed KOR agonist. 54 Intravenous (IV) administration of MOR agonists (fentanyl, alfentanil, remifentanil, and morphine) evoked scratching in a dose-and time-dependent manner. However, the MOR agonist U-50488H and ␦-OR (DOR) agonist SNC80 did not cause an increase in scratching. This study revealed that IV administration of an OR antagonist (naltrexone, 0.0032-0.1 mg/kg) attenuated scratching induced by IV fentanyl (0.018 mg/ kg) or morphine (1 mg/kg) in a dose-dependent manner. However, a peripherally selective opioid antagonist (quaternary naltrexone 0.0032-0.32 mg/ kg) did not block IV fentanyl-or morphine-induced scratching. Moreover, a histamine antagonist (diphenhydramine 0.1-10 mg/kg) failed to attenuate scratching induced by morphine, indicating that histamine does not transmit opioid-induced pruritus centrally. Pretreatment with clocinnamox, a selective MOR antagonist, inhibited intrathecal morphineinduced scratching in primates, but neither KOR (binaltorphimine) nor DOR antagonists (naltrindole) produced this effect. 55 Kjellberg et al conducted a systematic survey of the antipruritic effects in surgical patients receiving opioids. They found that many MOR antagonists, for example, intravenous naloxone and oral naltrexone, were efficacious. 53, 56 The effectiveness of methylnaltrexone, an opioid antagonist with orphan drug status, for the treatment of opioid-induced adverse effects is currently being investigated. Yuan et al 57 have reported the efficacy of oral methylnaltrexone capsules for the treatment of morphineinduced pruritus in a randomized, double-blind, placebo-controlled trial. In their study, 10 healthy volunteers were given oral placebo-intravenous morphine (0.05 mg/kg), oral methylnaltrexone (0.64 mg/kg)-intravenous morphine (0.05 mg/ kg), or oral methylnaltrexone (19.2 mg/kg)-intravenous morphine (0.05 mg/kg) in a crossover fashion. Morphine was injected 20 min after placebo or methylnaltrexone ingestion. The sessions were separated by at least 1 week. Subjective measures of opioid-induced adverse effects were evaluated using a 5-point scale ranging from 0 (no symptoms) to 4 (extreme itching). Central nervous system effects, such as "coasting" and being "spaced out," were also assessed. They found that methylnaltrexone did not cause a change in the psychological effects of morphine, but it effectively reversed the skin itch effects. In addition, oral methylnaltrexone at a dose of 19.2 mg/kg significantly reduced four of the subjective effects after intravenous administration of morphine. Their results indicate peripheral locations for these effects. Greater knowledge of these skin-associated opioid interactions will be important for the treatment of chronic and acute pain and pruritus. 6 
POSSIBLE LINK BETWEEN OPIOIDS AND PRURITUS IN POSTBURN PATIENTS
The treatment of severe pruritus in patients with hypertrophic scars continues to be a clinical challenge. Although the administration of antihistamines and application of moisturizing lotions are currently the therapies of choice for postburn itch, few patients benefit from their use. 4 We conducted a research on the symptom and mechanism of postburn itch to gain new insights into understanding and treating the disorder. ure 1). Several mechanisms have been suggested to explain opioid-induced pruritus. Histamine is believed to be a key mediator of itching produced by orally administered opioids. Some opioids, such as morphine or codeine, may induce histamine release from mast cells in a nonimmunological manner. 58 Thus, itching can be diminished by H1 antihistamines, but not by naloxone; this indicated that histamine release is not mediated by ORs. 56 However, it cannot be excluded that pruritus may also be evoked by direct activation of ORs that have recently been identified in the skin. 59 Other mediators involved in both scar metabolism and itching include vasoactive peptides, such as kinins and prostaglandins of the E series (prostaglandin E), and thinly myelinated and unmyelinated C-fibers in the skin. 4 Direct mechanical stimulation of nerve endings during scar remodeling may account, at least in part, for the itch sensation experienced by patients with immature, abnormal, or elevated scars. 60 Previous data showed that peripheral MORs are localized in the peripheral nerve endings in the upper dermis and the epidermis and indicated that human keratinocytes and nerve endings communicate through the MORs with its ligand, ␤-endorphin. The colocalization experiments revealed that the peripheral nerve fibers in the upper dermis and epidermis express the MORs and that these nerve fibers are unmyelinated. ORs (MOR and DOR) have already been identified on the peripheral sensory nerve fibers and their terminal endings. 61 Although peripheral ORs are largely expressed by primary sensory neurons, they are functionally inactive under most basal conditions. However, with tissue injury or inflammation, the action of bradykinin on the B2 receptor improves the efficiency of MOR coupling to G␣ and promotes MOR signaling. 62 There are multiple pathways by which endogenous opioids can gain access to injured sites to activate MORs in the peripheral tissue. The cannabinoid (CB) agonists bind to the peripheral CB2 receptors and cause CB2 activation, with subsequent stimulated release of ␤-endorphin from skin keratinocytes. 37 Because opiates, such as morphine, are commonly used to control pain in burn patients 63 and the induction of pruritus is known to occur after opiate administration, 64 exogenous opioids may play a role in the induction of itch in postburn patients, but this mechanism has not been clearly delineated. If pruritus after burn is related to opiate administration, treatment with opioid antagonists should be recommended. 37 However, to the best of our knowledge, the use of opioid antagonists has not been investigated in patients with burn injuries. Bigliardi et al 65 first reported MOR protein expression in human skin more than a decade ago. This was followed by further reports on MOR, DOR, and KOR, and the endoge- nous ligands, ␤-endorphin, 5, 39 enkephalins, 66 and dynorphins, 59 in the epidermis and peripheral nerve fibers. 67 The MOR is expressed in all layers of the epidermis. In the dermis, the MOR is expressed in the adnexal structures, particularly in the ducts of sweat glands, sebaceous glands, and the pilosebaceous unit of hair follicles. 6 Although previous studies have demonstrated that both MOR antagonists and KOR agonists are effective in alleviating intrathecal morphine-induced itch in primates, 68 ,69 the precise role of each subtype of ORs in processing the itch sensation is still an enigma.
In a recent study, we demonstrated that the expression of MOR, KOR, and DOR is significantly increased in the epidermis and dermis of patients with hypertrophic scars and cacesthesia. 5 Moreover, the expression of ␤-endorphin, a MOR ligand, was observed to be markedly higher in hypertrophic scars than in normal skin. 70 Our data suggested that the opioid system might be activated in hypertrophic scars and might contribute to the modulation of peripheral nociception in hypertrophic scars. 5 In fact, all three subtypes of ORs were found to interact with each other. When one receptor subtype is occupied by its agonist, the other receptors might undergo a conformational change, and this might enhance the coupling with their respective agonists. 71 Therefore, the cacesthesia might be the net result of the interactions between the opioids and their receptors.
PERSPECTIVES
The exploration of the frontiers in pruritus research reveals that we still lack a single, universally effective, pharmacological strategy for combating itch in postburn patients, mainly because of the inherent neurophysiological and neuroimmunological complexity of itch pathogenesis. It would be naive to expect that such a one-shot cure for itch would become available in the near future. Although the generation of itch in postburn patients with hypertrophic scars is very complex and involves the interactions between the central and peripheral nervous system and the skin, a broad but concrete spectrum of molecular targets for effective control of itching intervention has emerged. There is increasing evidence on the pivotal role played by ORs in the modulation of pruritus in the postburn patients. The successful use of naltrexone, an opioid antagonist, in treating pruritus in other patient populations suggested that opioid antagonists may also be effective in patients with hypertrophic scars and that they may be used as potential therapeutic drugs for burn-related pruritus in the future. Undoubtedly, we will move much closer to developing more effective therapeutic strategies for pruritus treatment. The opioids and their receptors in the central and peripheral nervous system and skin need to be further explored systematically, and the precise role of each subtype of ORs in processing itch sensation should also be investigated. Such research may pave the way for developing innovative and more effective approaches to manage itching in postburn patients.
